Favlin Injection contains Lincomycin at a concentration of 300mg/ml, a potent antibiotic belonging to the lincosamide class, primarily used to treat serious bacterial infections caused by susceptible strains of gram-positive cocci and anaerobic bacteria. It is particularly effective against infections where penicillin is contraindicated or ineffective, including skin and soft tissue infections, respiratory tract infections, bone and joint infections, and septicemia. Favlin works by inhibiting bacterial protein synthesis, thereby halting bacterial growth and proliferation. Administered via intramuscular or intravenous injection, it ensures rapid therapeutic levels in the bloodstream, making it suitable for severe infections requiring prompt intervention. Dosage and duration depend on the severity of the infection and patient-specific factors such as renal function. Common side effects may include gastrointestinal disturbances, rash, and injection site reactions, while rare but serious adverse effects include Clostridium difficile-associated diarrhea and hypersensitivity reactions. Caution is advised in patients with a history of hypersensitivity to lincomycin or clindamycin, and it should be used judiciously to prevent antibiotic resistance. Favlin Injection should only be used under medical supervision, with appropriate microbiological guidance to ensure efficacy and safety.